Clinical Trial

Efficacy and Safety of Maridebart Cafraglutide in Adult Participants With Type 2 Diabetes Mellitus Who Have Obesity or Are Overweight

Name: Efficacy and Safety of Maridebart Cafraglutide in Adult Participants With Type 2 Diabetes Mellitus Who Have Obesity or Are Overweight — clinical trial record (NCT06858878)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Study acronym: MARITIME-2

Active, Not Recruiting Phase 3

View on ClinicalTrials.gov →

Summary

The primary objective of this study is to demonstrate that maridebart cafraglutide is superior to placebo for percent change in body weight.

Trial Details

NCT Number	NCT06858878
Lead Sponsor	Amgen
Conditions	Type 2 Diabetes Mellitus (T2DM), Obesity, Overweight
Enrollment	1,105 participants
Start Date	2025-03-17
Primary Completion	2027-01-21 (estimated)
Study Completion	2027-04-16 (estimated)
Updated on ClinicalTrials.gov	2025-12-31